PAH Data Download: The Ins and Outs of Multiple Models
Over the past 5 years our laboratories have conducted numerous studies with various models of pulmonary hypertension.
We are looking forward to sharing some our findings next week at the Safety Pharmacology Society Annual meeting in Washington, D.C. in a lunch and learn on Monday, October 20th.
We will be discussing results from our monocrotaline and hypoxia experiments as well as sharing our large datasets generated from clinical treatments in our gold standard model–the hypoxia/VEGF receptor antagonist exposed rat. These results are very compelling – and show differential effects of sildenafil at 3, 4, 6 and 12 weeks into the hypoxia/VEGF model.
Over the past year, our labs have also conducted studies with an alternative preclinical model of PAH – the athymic nude rat treated with VEGF receptor antagonist. This model may be applicable to a certain subset of PAH patients where inflammation appears to play a major pathogenic role.
If you are at SPS – stop over for some lunch accompanied by an in depth data dissection from various models of pulmonary arterial hypertension.
For those that are not attending – check our website after the SPS meeting where you’ll be able to download the slide deck from our presentation.
Related Posts via Categories
- Cardiovascular Preclinical Consulting,
- Cardiovascular Studies,
- Safety Pharmacology Society